August 24, 2020 -- RNAimmune has secured $2.35 million in seed round financing from multiple venture capital firms to advance its COVID-19 vaccine RV1730 program and neoantigen-based cancer vaccine programs.
Since its establishment as a spinoff of Sirnaomics earlier this year, RNAimmune has deployed its in-house artificial intelligence algorithm for epitope prediction and validation (ALEPVA) for mRNA vaccine and drug design, licensed global exclusive rights for polypeptide-lipid nanoparticle (PLNP) delivery technology, and adopted a large-scale good manufacturing practice manufacturing knowhow from Sirnaomics.
The company is preparing for an investigational new drug filing for RV1730 and is working on advancing its cancer vaccine pipeline.
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
